CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03226249
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:08.307069+00:00
- Published At
- 2020-07-15T00:00:00+00:00
- Record Updated At
- 2023-06-02
- Results Posted At
- 2020-07-15
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Classical Hodgkin Lymphoma", "Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Lymphocyte-Rich Classical Hodgkin Lymphoma", "Mixed Cellularity Classical Hodgkin Lymphoma", "Nodular Sclerosis Classical Hodgkin Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-06-02"- protocolSection.identificationModule.nctId
"NCT03226249"- protocolSection.identificationModule.officialTitle
"Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-07-15"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.